Biohaven's stock jumps 12% after saying its migraine drug had $93 million in sales in Q2

3 weeks ago 8

Shares of Biohaven Pharmaceutical Holding Co. Ltd. BHVN, +7.61% were up 12.1% successful premarket trading connected Wednesday aft the institution said its caller migraine attraction brought successful $93 cardinal successful income successful the 2nd 4th of 2021. The drug, Nurtec Odt, tin beryllium utilized to dainty and forestall migraines. It has generated a full of $200 cardinal successful nett gross since launching successful the U.S. successful March 2020. Biohaven's banal is up 15.3% for the year, portion the broader S&P 500 SPX, +0.05% has gained 15.6%.

Read Entire Article